Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
McKinsey
Medtronic
Dow
Merck

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,017,760

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,017,760
Title: Isolation and culture of porcine hepatocytes
Abstract:A perfusion device such as a liver assist device containing a housing defining a perfusion inlet and a perfusion outlet, a porous membrane structure mounted within said housing to define a perfusion compartment and an adjacent hepatocyte compartment, and porcine hepatocytes isolated from a porcine liver by retrograde perfusion.
Inventor(s): Jauregui; Hugo O. (Providence, RI), Naik; Sharda (Cranston, RI), Santangini; Henry (Cranston, RI), Trenkler; Donna M. (Greene, RI)
Assignee: Rhode Island Hospital (Providence, RI)
Application Number:08/541,462
Patent Claims:1. An isolated sample of primary porcine hepatocytes, comprising at least 9% pericentral cells, wherein said cells retain metabolic activity for at least 24 hours in vitro.

2. The sample of claim 1, wherein said sample comprises at least 10% pericentral cells.

3. The sample of claim 1, wherein said sample is characterized by:

(a) diazepam metabolic activity of at least 3 .mu.g/ml total diazempam metabolites per hour;

(b) 7-ethoxycoumarin metabolic activity of at least 0.25 .mu.g/ml 7-hydroxycoumarin per hour;

(c) acetaminophen metabolic activity of at least 10 .mu.g/ml acetaminophen glucuronide per hour;

(d) NH.sub.3 metabolism of at least 45 .mu.g/ml NH.sub.3 per hour; or

(e) proliferative activity for at least 24 hours of in vitro culture.

4. The sample of claim 3, wherein said sample is characterized by:

(a) diazepam metabolic activity of at least 8 .mu.g/ml total diazempam metabolites per hour;

(b) 7-ethoxycoumarin metabolic activity of at least 1.5 .mu.g/ml 7-hydroxycoumarin per hour;

(c) acetaminophen metabolic activity of at least 25 .mu.g/ml acetaminophen glucuronide per hour;

(d) NH.sub.3 metabolism of at 60 .mu.g/ml of NH.sub.3 per hour; or

(e) proliferative activity for at least 10 days of in vitro culture.

5. A method of isolating a sample of primary porcine hepatocytes enriched for pericentral cells, comprising

(a) providing a pig;

(b) perfusing a liver from said pig in a retrograde manner with a solution that is free of digitonin;

(c) removing said liver from said pig;

(d) retrieving said hepatocytes from said liver; and

(e) separating said hepatocytes from cellular debris and non-parenchymal cells to yield said sample of hepatocytes, said sample comprising at least 9% pericentral cells, wherein said hepatocytes retain metabolic activity for at least 24 hours in vitro.

6. The method of claim 5, wherein said porcine liver is perfused with a buffered collagenase solution.

7. The method of claim 5, wherein step (b) is carried out in situ.

8. The method of claim 5, wherein said pig weighs at least 15 pounds.

9. The method of claim 8, wherein said pig weighs between 20-35 pounds.

10. The method of claim 5, wherein said pig is at least 6 weeks of age.

11. The method of claim 10, wherein said pig is between 6-8 weeks of age.

12. A method of enhancing viability and metabolic activity of porcine hepatocytes in vitro comprising:

(a) providing a sample of porcine hepatocytes in a suspension of particles; and

(b) culturing said suspension in a roller bottle, wherein said hepatocytes and said particles form aggregates which adhere to the wall of said roller bottle and wherein said hepatocytes proliferate for at least 24 hours of in vitro culture and are at least 2 times more metabolically active than a second sample of porcine hepatocytes cultured in a monolayer.

13. The method of claim 12, wherein said particles are microcarrier beads.

14. The method of claim 12, wherein said hepatocytes proliferate for at least 10 days of in vitro culture and metabolize at least 20 times more of a toxic compound than a second sample of porcine hepatocytes cultured in a monolayer.

15. The method of claim 14, wherein said compound is diazepam.

16. The method of claim 12, wherein said suspension comprises a medium comprising at least 5% fetal bovine serum.

17. The method of claim 12, wherein said suspension comprises a serum-free medium.

18. The method of claim 12, wherein said suspension comprises a medium comprising at least 1% dimethyl sulfoxide.

19. The method of claim 18, wherein said medium comprises insulin.

20. The method of claim 18, wherein said medium comprises transferrin.

21. The method of claim 18, wherein said medium comprises selenium.

22. The method of claim 18, wherein said medium comprises insulin, transferrin, selenium, and at least 2% DMSO.

23. The sample of claim 1, wherein said cells retain metabolic activity for at least 3 days in vitro.

24. The sample of claim 23, wherein said cells retain metabolic activity for at least 4 days in vitro.

25. The sample of claim 24, wherein said cells retain metabolic activity for at least 6 days in vitro.

26. The sample of claim 25, wherein said cells retain metabolic activity for at least 10 days in vitro.

Details for Patent 6,017,760

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04   Start Trial Rhode Island Hospital (Providence, RI) 2036-04-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Mallinckrodt
Boehringer Ingelheim
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.